More Access and Evidence Articles

Access and Evidence

Putting a price on life: Is the answer outside pharma?

Nicola Davies, (Nov 4, 2019)

Gene replacement and cell-based therapies are here to cure, but are we ready for them? The current difficulty pricing groundbreaking healthcare advancements suggests maybe not.
Access and Evidence

Putting The I in Pills

Izzy Gladstone, (Jun 27, 2019)

Individualised medicine has so far failed to live up to the hype but innovations in the field are on the cusp of disrupting the way pharma and healthcare develop and provide treatments.
Access and Evidence

Embracing Early Access

Katie Osborne, (Jan 22, 2019)

Compassionate use programs offer hope to patients who have ran out of options. But the benefits must be weighed against the risks.
Access and Evidence

RWE: The Missing Link

Nicola Davies, (Jan 7, 2019)

Linking real-world datasets is essential to deliver true insights
Access and Evidence

Gold Standard: Standardizing RWD

Nicola Davies, (Jan 4, 2019)

If real-world data is to deliver on its promise, it needs to be standardized
Access and Evidence

Blockchain: Solution Or Snake Oil?

Ross Davies, (Dec 19, 2018)

The potential of blockchain to better manage RWE and access makes it an exciting prospect. However, pharma first needs to get its head around the practical application.
Access and Evidence

VBCs: Are They Working?

Adam Chapman, (Dec 12, 2018)

Are value-based contracts actually improving patient access to new medicines?
Access and Evidence

Calling the Shots?

Katie Osborne, (Dec 10, 2018)

How influential are the value assessments from bodies like ICER?
Access and Evidence

Cutting Out the Middleman

Hugh Gosling, (Dec 7, 2018)

Are PBMs part of the problem or the solution?
Access and Evidence

Value-Based Contracting: Do We Have The Data?

Andy stone, (Nov 20, 2018)

Deals have been signed. Promises have been made. But are companies delivering the goods?

Pages